ARTICLE | Deals
CEO Ingram sees “the one significant strategic transaction” to transform Sarepta’s future, while Arrowhead preps for first-ever launch
By Paul Bonanos, Director of Biopharma Intelligence
November 26, 2024 9:11 PM UTC
A deal with Arrowhead will add four clinical and three preclinical programs to Sarepta’s pipeline, strengthening the former company’s balance sheet as it prepares for its first commercial launch.
Sarepta Therapeutics Inc. (NASDAQ:SRPT) is paying $500 million up front to Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) and investing $325 million for an equity stake in the biotech, at a premium price. Both companies’ shares rose by double digits Tuesday: Sarepta’s were up about 14%, with its market cap reaching nearly $12.5 billion, while Arrowhead gained 12% to attain a market cap of about $2.6 billion…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/654329/sarepta-broadens-pipeline-via-sirna-deal-with-arrowhead-paying-825m-up-front